The future of blood-based biomarkers in liver cancer.
Blood-based biomarkers show promise for early detection and management of liver cancer but require further validation in clinical settings.
- Why it matters: Effective biomarkers are crucial for improving early diagnosis, risk assessment, and treatment monitoring in liver cancer, yet most lack rigorous prospective validation.
- What they did: The review summarizes current blood-based biomarkers across the liver cancer care continuum, analyzing research efforts and emphasizing the need for clinical trials and cohort studies.
- The result: Advancing validation efforts will enable these biomarkers to become reliable tools in clinical practice, ultimately improving patient outcomes and personalized treatment strategies.